Palatin Technologies, Inc.

AMEX:PTN

Biotechnology

Healthcare
$9.09 -0.82%

-$0.10 today

Market cap
$236.39M
Beta
0.94
P/E (TTM)
-1.9
EPS (TTM)
-$6.43
52W Low $5.00High $31.00

Volume 0.02M

Average 1.78M

PTN EBITDA

Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.

Palatin Technologies, Inc.AMEX: PTN

EBITDA · Q3 FY2026 · quarter ended Mar 2026

EBITDA remains negative

Q3 FY2026 EBITDA was -$1.41M, compared with -$4.76M a year earlier. Trailing-twelve-month EBITDA was -$6.14M.

Context

  • EBITDA grew in size in 1 of the last 3 fiscal years.
  • FY2025 was the smallest annual figure in the 4 fiscal years shown.

What to watch

Whether EBITDA reaches the consensus estimate from 1 analysts of -$14.9M (+12.5%) for the fiscal year ending Jun 2026, a slowdown from the +42.0% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-$1.41M+80.5% QoQ
Last fiscal yearJun 2025
-$17.03M+42.0% YoY
LTMMar 2026
-$6.14M+73.2% YoY
EBITDA past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+70.3%——
1 year+42.0%+12.5%-29.5 pp
3-year CAGR———
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA history

USD · from the income statement

Latest · FY2025
(17.03M) USD
Year-over-year change
+42.0%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA vs competitors

How PTN compares with its peers on the latest reported figures

  • PTN's LTM Mar 2026 EBITDA of -$6.14M is the lowest of the 2 companies compared; the peer median is $22.15M.
  • Its year-over-year change of +73.2% is the lowest of 2, against a peer median of +154.8%.
  • EBITDA amounts to 47.7% of revenue for PTN, versus a peer median of 41.2%.
PTN Competitors Peer median
EBITDA for PTN and competitors
Company Period LTM YoY 3-year CAGR% of revenue
QTTBQ32 Bio Inc.LTM Mar 2026$22.15M +154.8%—41.2%
PTNPalatin Technologies, Inc.LTM Mar 2026-$6.14M +73.2%—47.7%
Peer median (excluding PTN) $22.15M+154.8%—41.2%

Competitors are the stored peer set for PTN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Jun 2021
FY2022
Jun 2022
FY2023
Jun 2023
FY2024
Jun 2024
FY2025
Jun 2025
Revenue(188.6K)1.47M4.85M4.49M0
Cost of Revenue147.84K217.53K418.47K97.64K0
Gross Profit(336.44K)1.25M4.44M4.39M0
Gross Margin178.4%85.2%91.4%97.8%—
Research & Development12.93M21.33M22.63M22.4M14.9M
Selling, General & Admin17.34M16.51M15.29M12.27M7.81M
Operating Expenses33.05M37.84M36.89M26.89M17.46M
Depreciation & Amortization51.12K486.02K288.33K339.08K258.92K
EBITDA(33.52M)(35.68M)(28.4M)(29.38M)(17.03M)
EBITDA Margin17774.4%-2429.9%-585.2%-654.3%—
Operating Income(33.38M)(36.59M)(32.46M)(22.5M)(17.46M)
Operating Margin17701.3%-2491.6%-668.7%-501.0%—
Interest Income23.57K0000
Interest Expense029.68K20.01K17.11K15.03K
Other Income / Expenses(212.39K)390.15K3.75M(7.24M)152.59K
Income Before Tax(33.6M)(36.2M)(28.71M)(29.74M)(17.31M)
Pre-Tax Margin17813.9%-2465.1%-591.5%-662.3%—
Income Tax Expense00(4.67M)00
Net Income(33.57M)(36.2M)(24.04M)(29.74M)(17.31M)
Net Margin17799.2%-2465.1%-495.2%-662.3%—
EPS (Basic)(3.55)(3.79)(2.21)(2.02)(32.15)
EPS (Diluted)(3.55)(3.79)(2.21)(2.02)(32.15)
Weighted Avg Shares9.47M9.54M10.89M14.7M538.35K
Weighted Avg Shares (Diluted)9.47M9.54M10.89M14.7M538.35K

Palatin Technologies, Inc.

AMEX:PTN

Intrinsic Alpha fair value

Locked

Current Price

$9.09

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.